For the quarter ending 2025-09-30, ZVRA made $26,063K in revenue. -$544K in net income. Net profit margin of -2.09%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenue, net | 26,063 | 25,881 | 20,401 | 3,695 |
| Intangible asset amortization | - | - | 1,615 | 1,545 |
| Cost of product revenue | 1,238 | 12,379 | 1,345 | 2,303 |
| Intangible asset amortization | 315 | 1,616 | - | - |
| Impairment of intangible assets | 0 | 58,710 | - | - |
| Research and development | 3,432 | 3,433 | 3,258 | 10,945 |
| Selling, general and administrative | 16,935 | 20,782 | 19,545 | 16,208 |
| Total operating expenses | 20,367 | 24,215 | 22,803 | 27,153 |
| Income (loss) from operations | 4,143 | -71,039 | -5,362 | -27,306 |
| Us-gaap_fairvalueadjustmentofwarrants | - | - | - | 4,746 |
| Gain on sale of prv | 0 | 148,325 | - | - |
| Interest expense | 2,051 | 2,009 | - | 2,312 |
| Fair value adjustment related to warrant and cvr liability | 5,506 | 747 | - | - |
| Fair value adjustment related to investments | -124 | 2 | - | -90 |
| Interest and other income, net | 2,313 | 2,378 | - | 1,049 |
| Total other (expense) income | -5,120 | 147,945 | 3,445 | -5,919 |
| (loss) income before income taxes | -977 | 76,906 | -1,917 | -33,225 |
| Income tax benefit (expense) | -433 | 2,199 | 1,182 | - |
| Net (loss) income | -544 | 74,707 | -3,099 | -33,225 |
| Basic (in dollars per share) | -0.01 | 1.24 | -0.06 | -0.69 |
| Basic (in shares) | 55,951,572 | 54,781,000 | 54,095,543 | 47,808,817 |
| Diluted (in dollars per share) | -0.01 | 1.21 | - | - |
| Diluted (in shares) | 55,951,572 | 56,325,000 | - | - |
ZEVRA THERAPEUTICS, INC. (ZVRA)
ZEVRA THERAPEUTICS, INC. (ZVRA)